Immunology and Bi...
Follow
Find tag "#monoclonal antibody"
7.6K views | +3 today
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert Faure au nom de l'ASSIM from Melanoma BRAF Inhibitors Review
Scoop.it!

Clinical deployment of antibodies for treatment of melanoma

Abstract

The concept of using immunotherapy to treat melanoma has existed for decades. The rationale comes from the knowledge that many patients with melanoma have endogenous immune responses against their tumor cells and clinically meaningful tumor regression can be achieved in a minority of patients using cytokines such as interleukin-2 and adoptive cellular therapy. In the last 5 years there has been a revolution in the clinical management of melanoma in large measure based on the development of antibodies that influence T cell regulatory pathways by overcoming checkpoint inhibition and providing co-stimulation, either of which results in significantly more effective immune-mediated tumor destruction. This review will describe the pre-clinical and clinical application of antagonistic antibodies targeting the T-cell checkpoints cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1), and agonistic antibodies targeting the costimulatory pathways OX40 and 4-1BB. Recent progress and opportunities for future investigation of combination antibody therapy will be described.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, March 9, 3:56 AM

Highlights

 

Melanoma treatment has been transformed using T-cell checkpoint antibodies.

Antibodies to CTLA-4 and PD-1 have had the largest impact on melanoma management.

Combination T-cell checkpoint therapy holds great promise for clinical development.

OX40 and 4-1BB are T cell costimulators with clinical potential in melanoma.

 

 

Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Mode of Action: Lindis Biotech

Mode of Action: Lindis Biotech | Immunology and Biotherapies | Scoop.it

Ektomun® is a member of the highly innovative, validated family of Triomab® antibodies. It combines the halves of two distinct full-size antibodies, a GD2-specific mouse antibody and a T -cell specific rat antibody, in one molecule.

 

GD2 is a clinically validated tumor target opening many potential applications for ektomun®. It is broadly present in tumors of neuroectodermal origin, including small cell lung cancer (SCLC), melanoma, neuroblastoma and glioblastoma. In healthy tissues, however, GD2 expression is strictly limited to very few, distinct cell types.

 

Due to its trifunctional design, ektomun® can simultaneously bind to GD2, expressed by  tumor cells, to a T-cell and, via its Fc-region, to an accessory cell of the innate immune system, as e.g. macrophages, dendritic or NK cells.

 

The resulting tri-cell-complex triggers multiple immune mechanisms at the same time.  Not only are tumor cells specifically and potently destroyed, but a long-lasting anti-tumor immunity is also induced – an effect that can otherwise only be achieved through vaccination.


Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

KB001-A

KB001-A | Immunology and Biotherapies | Scoop.it
Learn more about KB001-A study to prevent or treat a common opportunistic gram negative bacterium, Pseudomonas aeruginosa (Pa)

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, November 12, 2014 4:18 AM

KaloBios’ patented proprietary Humaneered® technology platform is designed to address problems of therapeutic antibodies (e.g., specificity, affinity, immunogenicity etc.), as well as equally important downstream processing issues (e.g., solubility, expression, aggregation, etc.). The process is fast and produces antibodies close to human germ-line in sequence while retaining the specificity and improving the affinity of the reference antibody. Humaneered® antibodies have now been tested clinically and to date no anti-drug antibodies have been detected even after dosing healthy human volunteers.

 

Engineered humanLow/No immunogenicityEqual or higher affinity than starting antibodyFastSolves antibody problems:AggregationStabilityExpression level (in both mammalian and microbial systems)Binding kinetics (select for Ka vs. Kd)

This novel system allows a true alternative to classic antibody engineering technologies, bringing a cost advantage to our pipeline as well as the opportunity to provide service to others.

Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Engineered Fc based antibody domains and fragments as novel scaffolds

Highlights

 

Engineering of smaller antibody scaffolds can overcome the limitations of full-size antibodies.

This review focuses on engineered IgG1 Fc based antibody fragments and domains as novel scaffolds.

The Fc based binders are promising candidate therapeutics with small size and long half-lives.

 

Abstract

Therapeutic monoclonal antibodies (mAbs) have been successful for the therapy of a number of diseases mostly cancer and immune disorders. However, the vast majority of mAbs approved for clinical use are full size, typically in IgG1 format. These mAbs may exhibit relatively poor tissue penetration and restricted epitope access due to their large size. A promising solution to this fundamental limitation is the engineering of smaller scaffolds based on the IgG1 Fc region. These scaffolds can be used for the generation of libraries of mutants from which high-affinity binders can be selected. Comprised of the CH2 and CH3 domains, the Fc region is important not only for the antibody effector function but also for its long half-life. This review focuses on engineered Fc based antibody fragments and domains including native (dimeric) Fc and monomeric Fc as well as CH2 and monomeric CH3, and their use as novel scaffolds and binders. The Fc based binders are promising candidate therapeutics with optimized half-life, enhanced tissue penetration and access to sterically restricted binding sites resulting in an increased therapeutic efficacy. This article is part of a Special Issue entitled: Recent advances in molecular engineering of antibody.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, November 11, 2014 7:28 AM
Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics

Volume 1844, Issue 11, November 2014, Pages 1977–1982

Recent advances in molecular engineering of antibody

Review Engineered Fc based antibody domains and fragments as novel scaffolds ☆Tianlei Yinga, , , Rui Gongb, Tina W. Jua, Ponraj Prabakarana, c, Dimiter S. Dimitrova  DOI: 10.1016/j.bbapap.2014.04.018
Scooped by Gilbert Faure au nom de l'ASSIM from Multiple sclerosis New Drugs Review
Scoop.it!

Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.

Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. | Immunology and Biotherapies | Scoop.it

Interleukin-2 receptor α chain (CD25) is overexpressed in human T-cell leukemia virus 1 associated adult T-cell leukemia/lymphoma (ATL). Daclizumab a humanized monoclonal antibody blocks IL-2 binding by recognizing the interleukin-2 receptor α chain (CD25). We conducted a phase I/II trial of daclizumab in 34 patients with ATL. Saturation of surface CD25 on circulating ATL cells was achieved at all doses; however saturation on ATL cells in lymph nodes required 8mg/kg. Up to 8mg/kg of daclizumab administered every 3weeks was well tolerated. No responses were observed in 18 patients with acute or lymphoma ATL; however, 6 partial responses were observed in 16 chronic and smoldering ATL patients. The pharmacokinetics/pharmacodynamics of daclizumab suggest that high-dose daclizumab would be more effective than low-dose daclizumab in treatment of lymphoid malignancies and autoimmune diseases (e.g., multiple sclerosis) since high-dose daclizumab is required to saturate IL-2R alpha in extravascular sites.

 

Highlights

 

Interleukin-2 receptor alpha chain (CD25) is overexpressed by ATL leukemia cells.

Daclizumab a humanized monoclonal antibody blocks IL-2 binding to CD25.

8 mg/kg of daclizumab is required to get ≥ 95% saturation of CD25 in lymph nodes.

Partial responses were observed in patients with chronic and smoldering ATL.

The study provides a rationale for high-dose treatment in lymphoid malignancies.

 


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, October 1, 2014 3:41 PM
Clin Immunol. 2014 Sep 26. pii: S1521-6616(14)00223-X. doi: 10.1016/j.clim.2014.09.012. [Epub ahead of print]Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.Berkowitz JL1, Janik JE1, Stewart DM1, Jaffe ES2, Stetler-Stevenson M2, Shih JH3, Fleisher TA4, Turner M5, Urquhart NE6, Wharfe GH6, Figg WD7, Peer CJ7,Goldman CK1, Waldmann TA8, Morris JC1.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Immunotherapy top 5 indications in clinical trials

Immunotherapy top 5 indications in clinical trials | Immunology and Biotherapies | Scoop.it

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, July 19, 2014 5:11 PM

The top 5 cancer types listed by the number of immunotherapy clinical trials, derived from ClinTrials.gov

 

Neoplasm Glandular/Epithelial     228

Neoplasm Nerves                                203

Carcinoma                                              192

Melanoma                                               127

Leukemia                                                  108

 

 

Gilbert Faure au nom de l'ASSIM's comment, July 20, 2014 3:42 AM
nice synthesis! I had recently a similar idea to write "capsules" on topics of interest
Krishan Maggon 's comment, July 21, 2014 10:17 AM
Very good idea, i wish there was a way to collaborate and place for collaborative efforts. thanks and best regards
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Best Selling Monoclonal Antibodies 2013

Best Selling Monoclonal Antibodies 2013 | Immunology and Biotherapies | Scoop.it

Via Krishan Maggon
Gilbert Faure au nom de l'ASSIM's insight:

impressive for immunologists so far away from so big amounts of money

more...
Krishan Maggon 's curator insight, January 6, 2014 8:38 AM

Abstract

 

A review of the best selling monoclonal antibodies in 2013 and 2012 is provided. Humira with sales of over $11 billion ($9.3 billion in 2012) remains the best selling monoclonal antibody, biologic as well prescription drug brand in 2013 as in 2012. The ranks of the next 4 top selling mabs remained unchanged from the 2012 Table.  Remicade (9.7 Bn), Rituxan (7.5 Bn) , Herceptin (6.5 Bn) and Avastin (6.5 Bn) were the second, third, fourth and fifth top selling mabs in 2013. The actual sales for 2013 as reported by the companies are provided. The total sales of the top selling blockbuster mabs were $63 billion in 2013. The actual global sales of all the approved blockbuster sales or potential (sales >1 billion) monoclonal antibodies in 2013 is provided. Besides the top 5 mabs, there were 2 other monoclonal antibodies with sales of over 2 billion dollars and 5 with sales of over $ 1 billion in 2013. In addition 5 recently launched mabs were nearing to reach sales of $ 1 billion this year. Currently 30 monoclonal antibodies are marketed in the US and Europe (January 2014).  Alexion Soliris was the most expansive marketed monoclonal antibody with a price tag of $440,000 per year of treatment, a sort of Rolls-Royce of mabs.

 

Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Affimed TandAbs and Trispecific Abs

Affimed develops TandAbs and Trispecific Abs for substantially increasing the efficacy and extend the therapeutic window by three proprietary platforms

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, November 22, 2014 10:21 AM

Early stage mab company, lead product AFM 13 for HL in Phase II trials.

Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies | Immunology and Biotherapies | Scoop.it
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies http://t.co/4XGxIKdg1U #immunotherapy #lungcancer #awareness #LCAM @OxfordJournals

 

Abstract

Despite extensive investigation over the past three decades, cancer immunotherapy has produced limited success, with few agents achieving approval by the Food and Drug Administration and even the most effective helping only a minority of patients, primarily with melanoma or renal cancer. In recent years, immune checkpoints that maintain physiologic self-tolerance have been implicated in the down-regulation of anti-tumor immunity. Efforts to restore latent anti-tumor immunity have focused on antibody-based interventions targeting CTL antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) on T lymphocytes and its principal ligand (PD-L1) on tumor cells. Ipilimumab, an antibody targeting CTLA-4, appears to restore tumor immunity at the priming phase, whereas anti-PD-1/PD-L1 antibodies restore immune function in the tumor microenvironment. Although ipilimumab can produce durable long-term responses in patients with advanced melanoma, it is associated with significant immune-related toxicities. By contrast, antibodies targeting either PD-1 or PD-L1 have produced significant anti-tumor activity with considerably less toxicity. Activity was seen in patients with melanoma and renal cancer, as well as those with non-small-cell lung, bladder and head and neck cancers, tumors not previously felt to be sensitive to immunotherapy. The tolerability of PD-1-pathway blockers and their unique mechanism of action have made them ideal backbones for combination regimen development. Combination approaches involving cytotoxic chemotherapy, anti-angiogenic agents, alternative immune-checkpoint inhibitors, immunostimulatory cytokines and cancer vaccines are currently under clinical investigation. Current efforts focus on registration trials of single agents and combinations in various diseases and disease settings and identifying predictive biomarkers of response.

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodiesTable 1.

Antibodies that target the PD-1 axis and are undergoing clinical investigation for cancer

 TargetAntibodyMolecular structureClinical development phaseTumor types in evaluationPD-1Nivolumab (BMS-936558)Fully human IgG4Phase IIIMelanoma, RCC, NSCLC, HNSCCPembrolizumab (MK-3475)Humanized IgG4Phase IIIMelanoma, NSCLCPidilizumab (CT-011)Humanized IgG1κPhase IIHEME, melanomaPD-L1BMS-936559Fully human IgG4Phase IAdvanced solid tumorsMPDL3280AFully human IgG1Phase IMelanoma, RCC, NSCLCPhase IIUROMEDI4736Fully human IgG1Phase IAdvanced solid tumorsPhase IIINSCLCMSB0010718CFully human IgG1Phase IAdvanced solid tumorsPhase IIMerkel cell carcinoma
Via Krishan Maggon
more...
Krishan Maggon 's curator insight, November 15, 2014 1:38 AM

Review of the current status of active PD1/PDL1 projects                    

 

 

Int. Immunol. (2014)doi: 10.1093/intimm/dxu095                                     First published online: October 16, 2014

 

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodiesGeorge K. Philips1 and Michael Atkins2

+Author Affiliations

1 Department of Medicine, Georgetown University Hospital, 3800 Reservoir Road NW, Washington DC 20007, USA2 Department of Oncology, Georgetown-Lombardi Comprehensive Cancer Center, Research Building-E501, 3970 Reservoir Road NW, Washington DC 20057, USACorrespondence to: G. K. Philips; E-mail: george.k.philips@gunet.georgetown.eduReceived September 4, 2014.Accepted October 3, 2014.
Krishan Maggon 's curator insight, November 15, 2014 2:06 AM

Review of the current status of active PD1/PDL1 projects                    

 

 

Int. Immunol. (2014)doi: 10.1093/intimm/dxu095                                     First published online: October 16, 2014

 

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodiesGeorge K. Philips1 and Michael Atkins2

+Author Affiliations

1 Department of Medicine, Georgetown University Hospital, 3800 Reservoir Road NW, Washington DC 20007, USA2 Department of Oncology, Georgetown-Lombardi Comprehensive Cancer Center, Research Building-E501, 3970 Reservoir Road NW, Washington DC 20057, USACorrespondence to: G. K. Philips; E-mail: george.k.philips@gunet.georgetown.eduReceived September 4, 2014.Accepted October 3, 2014.

Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Intracellular antibody capture: A molecular biology approach to inhibitors of protein–protein interactions

Abstract

Many proteins of interest in basic biology, translational research studies and for clinical targeting in diseases reside inside the cell and function by interacting with other macromolecules. Protein complexes control basic processes such as development and cell division but also abnormal cell growth when mutations occur such as found in cancer. Interfering with protein–protein interactions is an important aspiration in both basic and disease biology but small molecule inhibitors have been difficult and expensive to isolate. Recently, we have adapted molecular biology techniques to develop a simple set of protocols for isolation of high affinity antibody fragments (in the form of single VH domains) that function within the reducing environment of higher organism cells and can bind to their target molecules. The method called Intracellular Antibody Capture (IAC) has been used to develop inhibitory anti-RAS and anti-LMO2 single domains that have been used for target validation of these antigens in pre-clinical cancer models and illustrate the efficacy of the IAC approach to generation of drug surrogates. Future use of inhibitory VH antibody fragments as drugs in their own right (we term these macrodrugs to distinguish them from small molecule drugs) requires their delivery to target cells in vivo but they can also be templates for small molecule drug development that emulate the binding sites of the antibody fragments. This article is part of a Special Issue entitled: Recent advances in molecular engineering of antibody.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, November 12, 2014 3:51 AM
Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics

Volume 1844, Issue 11, November 2014, Pages 1970–1976

Recent advances in molecular engineering of antibody

Review Intracellular antibody capture: A molecular biology approach to inhibitors of protein–protein interactions ☆Jing Zhang, Terence H. Rabbitts  DOI: 10.1016/j.bbapap.2014.05.009
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy - Rao - Arthritis & Rheumatology - Wiley Online Library

An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy - Rao - Arthritis & Rheumatology - Wiley Online Library | Immunology and Biotherapies | Scoop.it
An evaluation of risk factors for major adverse #cardiovascular events during #tocilizumab therapy http://t.co/EymLTiXiv1 #rheum

 

Abstract

Objective. To explore associations of baseline and on-treatment lipid levels, inflammation, and rheumatoid arthritis (RA) disease activity with risk for major adverse cardiovascular events (MACE) in tocilizumab-treated RA patients.

Methods. In retrospective post hoc analyses, data were pooled from 3986 adults with moderate to severe RA administered ≥1 dose of tocilizumab 4 or 8 mg/kg intravenously every 4 weeks in randomized controlled trials and extension studies. Cox proportional hazards modeling was used to evaluate associations among baseline characteristics and posttreatment initiation variables (week 24) and change from baseline to week 24 disease activity and laboratory values, with risk for future MACE during extended follow-up.

Results. There were 50 independently adjudicated cases of MACE during 14,683 patient-years (PY) of follow-up (0.34 MACE/100 PY). At baseline, age, history of cardiac disorders, disease activity score using 28 joints (DAS28), and total cholesterol/high-density lipoprotein ratio were independently (P<0.05 for all) associated with MACE in multivariable models. On treatment, higher DAS28 scores and swollen and tender joint counts at week 24 were associated with future MACE. In separate models, greater reductions in DAS28 score and joint counts from baseline to week 24 were inversely associated with future MACE; changes in lipid parameters were not statistically significantly associated with risk for MACE.

Conclusion. As in the general population, an association was observed between baseline total cholesterol/high-density lipoprotein ratio and increased risk for MACE. Risk for on-treatment MACE, however, was found to be associated with control of disease activity but not lipid changes. Larger studies are needed to confirm these findings. © 2014 American College of Rheumatology.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, October 28, 2014 2:46 AM
An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapyVijay U. Rao MD, PhD1,†, Andrey Pavlov PhD2, Micki Klearman MD1,*, David Musselman MD1, Jon T. Giles MD, MPH3,Joan M. Bathon MD3, Naveed Sattar FRCPath, PhD4 andJanet S. Lee PhD5,‡

DOI: 10.1002/art.38920

Copyright © 2014 American College of Rheumatology

Issue

Arthritis & Rheumatology

Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.)

Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Amgen And Sanofi Compete To Launch New Class Of Cholesterol-Fighting Drugs

Amgen And Sanofi Compete To Launch New Class Of Cholesterol-Fighting Drugs | Immunology and Biotherapies | Scoop.it
Amgen, Inc. (NASDAQ:AMGN) has filed a Biologics License Application with the FDA for a new class of cholesterol-fighting drugs. It is competing with Sanofi SA (ADR) (NYSE:SNY) to be the first to tap into the $10 billion market.

Via Krishan Maggon
Gilbert Faure au nom de l'ASSIM's insight:

immunological molecules everywhere

more...
Krishan Maggon 's curator insight, August 29, 2014 8:37 AM

Evolocumab vs Alirocumab market war to dominate the new mabs superstatins market worth $10 billion.

 

These mabs discussed in previous  scoops.

Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Cellectis French touch in Cancer Immunotherapy attracts Pfizer

Cellectis French touch in Cancer Immunotherapy attracts Pfizer | Immunology and Biotherapies | Scoop.it

Engineered T cell CAR therapy

 

A revolution is taking place in the field of adoptive immunotherapy, where T cells armed with a Chimeric Antigen Receptor (CAR) are being used to fight cancerous cells. Genome engineering is at the heart of this revolution. This groundbreaking technology relies mainly on the use of engineered nucleases and makes it possible to modify the genome of the T cell to give it new properties. Specifically, the engineered T cell can be transformed into an allogeneic product, or it can resist existing cancer treatments or even overcome checkpoint inhibition. Genome engineering is regarded as one of the most important breakthroughs of recent years, and is about to revolutionize immunotherapy. 

Decades of research have shown that it is possible to improve the ability of T cells to fight diseases by genome engineering. For example, T cells can be engineered by adding a new gene (called a chimeric antigen receptor or CAR) that will boost their ability to recognize and destroy cancer cells. Another possibility for T cells is to inactivate an existing gene that damages the immune response.

The possibilities provided by T cell genome engineering are endless. Very sophisticated strategies can be designed at will to open the door for a new era of treatments in indications such as infectious diseases, autoimmune diseases, and cancer.

 

Chimeric Antigen Receptors (CARs) are artificial molecules that, when present at the surface of immune effector cells, will enable them to recognize a desired protein (antigen) and trigger the killing of cells harboring this antigen at their surface (target cells).

These receptors are becoming one of the most promising approaches to fight cancer, through the development of adoptive cell transfer therapies. Indeed, immune cells (most usually T-lymphocytes) can be engineered to express a CAR able to recognize proteins present at the surface of cancer cells. Upon cell-to-cell contact between effector and targeted cells, antigen recognition will activate the effectors, giving them the signal to attack their targets, and leading ultimately to the killing of cancer cells.

CARs are constructed by assembling domains from different proteins, each of which enables the chimeric molecule to carry out specific functions. The most common CAR architecture comprises an extracellular domain containing a region that recognizes the targeted antigen and a spacer region that links it to the transmembrane domain (the part of the protein that spans the cellular membrane). This is then followed by an intracellular domain, responsible for transmitting an activation signal to the cell upon antigen recognition, causing the CAR-engineered cell to attack the tumor cell.

The target-binding moiety is usually derived from an antibody, while the intracellular portion can include, besides the domain leading to cell activation and cytotoxic response, one or more domains from co-stimulatory receptor proteins that could enhance the proliferative capacity and survival of the “therapeutic” cells.

Cellectis is currently developing a collection of CARs targeting antigens present on cells from various types of cancer, as well as a proprietary multi-chain architecture of these artificial receptors, aiming to further increase the efficacy of adoptive cell therapies in the future.





CELLECTIS’ UCART19 RECEIVES ADVANCED-THERAPY MEDICINAL PRODUCT CLASSIFICATION FROM EMAJune 23, 2014

 

READ MORE READ THE PRESS RELEASEPFIZER AND CELLECTIS ENTER INTO GLOBAL STRATEGIC CANCER IMMUNOTHERAPY COLLABORATIONJune 18, 2014 


Via Krishan Maggon
more...
Krishan Maggon 's comment, July 16, 2014 11:24 AM
thanks a lot, I think this is an important development and a big vote of confidence from big pharma in Cellectis CAR and bioengineered T cells. Great day for French R&D and start up companies in Immunotherapy.
Krishan Maggon 's comment, July 16, 2014 11:26 AM
I wonder why the total number of visitors and page view remains too low. I think it is the absence from the USA market of Scoop it?
Gilbert Faure au nom de l'ASSIM's comment, July 16, 2014 12:05 PM
what are you refereeing to? I will send you the draft of a summary for a meeting Science&You next year where I want to submit a talk or a session about curation. Check your e-mail to-morrow.